



OPEN Profile of sleep disturbances in patients with recurrent depressive disorder or bipolar affective disorder in a tertiary sleep disorders service

Panagis Drakatos^{1,2,3,12}, David O'Regan^{1,2,3,12}, Yingqi Liao³, Constantinos Panayiotou³, Sean Higgins^{1,3}, Renata Kabiljo^{3,4}, Joshua Benson¹, Norman Pool⁵, Masoud Tahmasian⁶, Andrea Romigi⁷, Alexander Nesbitt^{1,3,8}, Paul R. A. Stokes⁹, Veena Kumari¹⁰, Allan H. Young¹¹ & Ivana Rosenzweig^{1,3}✉

Bidirectional relationship between sleep disturbances and affective disorders is increasingly recognised, but its underlying mechanisms are far from clear, and there is a scarcity of studies that report on sleep disturbances in recurrent depressive disorder (RDD) and bipolar affective disorder (BPAD). To address this, we conducted a retrospective study of polysomnographic and clinical records of patients presenting to a tertiary sleep disorders clinic with affective disorders. Sixty-three BPAD patients (32 female; mean age $\pm$ S.D.: 41.8 ± 12.4 years) and 126 age- and gender-matched RDD patients (62 female; 41.5 ± 12.8) were studied. Whilst no significant differences were observed in sleep macrostructure parameters between BPAD and RDD patients, major differences were observed in comorbid sleep and physical disorders, both of which were higher in BPAD patients. Two most prevalent sleep disorders, namely obstructive sleep apnoea (OSA) (BPAD 50.8.0% vs RDD 29.3%, $P = 0.006$) and insomnia (BPAD 34.9% vs RDD 15.0%, $P = 0.005$) were found to be strongly linked with BPAD. In summary, in our tertiary sleep clinic cohort, no overt differences in the sleep macrostructure between BPAD and RDD patients were demonstrated. However, OSA and insomnia, two most prevalent sleep disorders, were found significantly more prevalent in patients with BPAD, by comparison to RDD patients. Also, BPAD patients presented with significantly more severe OSA, and with higher overall physical co-morbidity. Thus, our findings suggest an unmet/hidden need for earlier diagnosis of those with BPAD.

¹Sleep Disorders Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK. ²Faculty of Life Sciences and Medicine, King's College London, London, UK. ³Department of Neuroimaging, Sleep and Brain Plasticity Centre, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, De Crespigny Park, Box 089, London SE5 8AF, UK. ⁴Department of Biostatistics and Health Informatics, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Denmark Hill, London SE5 8AF, UK. ⁵Department of Neuropsychiatry, St George's Hospital, South West London and St George's Mental Health NHS Trust, London, UK. ⁶Institute of Neuroscience and Medicine Research, Brain and Behaviour (INM-7), Jülich Research Center, Jülich, Germany & Institute for Systems Neuroscience, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany. ⁷IRCCS Neuromed Istituto Neurologico Mediterraneo Pozzilli (IS), Pozzilli, Italy. ⁸Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, London, UK. ⁹Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. ¹⁰Division of Psychology, Department of Life Sciences, & Centre for Cognitive Neuroscience, College of Health, Medicine and Life Sciences, Brunel University London, London, UK. ¹¹Department of Psychological Medicine, King's College London & South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology and Neuroscience, Bethlem Royal Hospital, Beckenham, UK. ¹²These authors contributed equally: Panagis Drakatos and David O'Regan. ✉email: ivana.1.rosenzweig@kcl.ac.uk

Associations between sleep disturbances and affective disorders such as the Bipolar Affective Disorder (BPAD) and Recurrent Depressive Disorder (RDD) have been increasingly recognised^{1–3}. Whilst sleep of inadequate quality often precedes a depressive episode and increases the risk for the development of affective disorders, mood of heightened negative or positive valence during wakefulness can also disrupt the normal sleep pattern⁴. Although disturbed sleep is considered to be a key symptom of psychiatric disorders in standard diagnostic manuals (i.e. Diagnostic and Statistical Manual of Mental Disorders-V (DMS-V)⁵ and International Classification of Diseases (ICD)⁶), the presentation of sleep disturbances remains heterogeneous in affective disorders. Furthermore, whilst recent studies suggest a disrupted homeostatic and circadian drive to sleep as the link between sleep disturbances and RDD⁷, the bidirectional relationship between sleep and BPAD has yet to be fully understood^{8,9}. This is of note, especially given that sleep and circadian disturbances present the core symptoms across the lifespan of the patients, and likely serves a key role in the aetiology and the very course of BPAD^{7,9–11}. Gaining further insight into the sleep phenotypes of BPAD and RDD may be useful for understanding the underlying pathophysiology of affective disorders, providing differential markers of these affective disorders, and hence influencing the choice of treatment modality to improve symptom severity in affective disorders.

To that end, an exploratory retrospective study of polysomnographic and clinical records of patients presenting to a tertiary sleep disorders clinic with affective disorders was conducted. We were not able to observe any significant differences in the sleep macrostructure parameters between BPAD and RDD patients, but major differences were observed in their presenting co-morbidity. Moreover, in our (real-world tertiary) patient cohort, BPAD was more strongly associated with two most prevalent sleep disorders, namely with obstructive sleep apnoea (OSA) and insomnia. Thus, we then set to further characterise any possible differences in the OSA phenotypes in patients with BPAD and RDD, especially those suggesting possible differing underlying neuromechanisms.

Methods and materials

Participant selection. A retrospective exploratory cross-sectional study of polysomnographic recordings of patients with clinically confirmed psychiatric diagnoses of BPAD and RDD^{5,6} by their referring clinical specialists, who were investigated between 2015 and 2019 at a large tertiary Sleep Disorders Centre (Guy's Hospital (GSTT), London, United Kingdom), was conducted. The study was granted ethical approval by the GSTT Institutional Review Board on Human Research (Project No 9342, GSTT NHS); according to the strict national guidelines. The GSTT Institutional Review Board on Human Research waived the need of obtaining informed consent due to use of retrospectively ascertained anonymized data and due to the fulfilment of the following non-negotiable stipulations (1) the study protocol abided by the strictest patients' data confidentiality and (2) it complied with all requirements of EU General Data Protection Regulation and with the Declaration of Helsinki regulations.

We identified sixty-three BPAD patients (32 female; mean age $\pm$ S.D.: 41.8 ± 12.4) and 126 age- and gender-matched RDD patients (62 female; 41.5 ± 12.8) (Table 1). All patients with a diagnosis or a previous history of BPAD or RDD confirmed in their medical records and based on the International Classification of Mental and Behavioural Disorders⁶ were screened and selected for the exploratory (real-life) study. Patients were in a presumed full or partial remission, and no additional mood and affective symptoms severity measures were available. Given the main aims of our study were to identify differences in the sleep phenotypes between patients with BPAD and RDD, firstly we identified all patients with BPAD that fulfilled inclusion and exclusion criteria. Subsequently, all patients with RDD that also fulfilled exclusion and inclusion criteria were sought, and matched 2:1 for age, gender, and date of study, to all identified BPAD patients. Eligibility of patients was further reviewed individually based on their medical records. Patients with a documented history of acute neurological or other psychiatric conditions were excluded from the study, e.g. those in the acute psychotic episode. Additional exclusion criteria were: aged ≤ 18 years old; a split-night polysomnography study (PSG: i.e. a baseline sleep study followed by continuous positive airway pressure (CPAP) titration performed in the second half of the night); central events consisting more than 50% of the AHI, past or current history of substance abuse; past history of head injury or trauma, neurodegenerative disorders (e.g. Parkinson's disease).

Polysomnography acquisition. All subjects had undergone overnight PSG, and the subsequent sleep scoring was performed in accordance with American Academy of Sleep Medicine (AASM) by two experienced sleep technologists¹². The PSG comprised multiple channels: electroencephalogram (EEG, six channels), electrooculogram (EOG, two channels), chin, tibialis anterior electromyogram (EMG), electrocardiogram (ECG), pulse oximeter, thoracic and abdominal respiratory bands, position sensor, nasal flow cannula and infrared video recording¹³.

Sleep parameters included sleep architecture related variables (i.e. non rapid eye movement sleep stage 1 (NREM1), or rapid eye movement sleep stage (REM) as a percentage of total sleep time (TST); NREM1% of TST, REM% of TST), sleep continuity variables (i.e. TST, sleep onset latency, i.e. the amount of time between the first epoch of any sleep stage and the 'lights out'); REM onset latency, REML (i.e. the time taken to the first epoch of REM sleep after sleep onset); sleep efficiency, SE (i.e. total sleep time/total time in bed $\times 100$); wake after sleep onset (WASO); AI (i.e. number of arousals/TST); periodic limb movements index, PLMI (i.e. number of periodic limb movements/TST).

The sleep apnea metrics included the apnea hypopnoea index (AHI, number of apneas + number of hypopneas/TST), the supine- and non-supine-AHI, and the AHI related to the main sleep stages (AHI_{NREM}, AHI_{REM}). We also measured the proportion of the AHI of obstructive events that consists of obstructive hypopneas (HI/AHI) for the total sleep time, and for the NREM and REM sleep separately. A formula of Relative Density, AHI_(sleep stage)/AHI_(total), or AHI_(sleeping position)/AHI_(total) was also created to describe the subtypes of sleep apnoea by

	BPAD		RDD		Statistics	
	Mean	SD	Mean	SD	F	P value
Age (years)	41.8	12.4	41.5	12.8	0.0180	0.893
BMI (kg/m ²)	32.9	7.98	28.6	6.34	15.379	< 0.001*
	n	%	n	%	χ^2	P value
Gender (female)	32	50.8	62	49.2	0.0420	0.837
	Median	IQR	Median	IQR	U	P value
ESS	12.0	13.0	14.0	9.0	3407.0	0.888
Sleep macrostructure						
TST (min)	379	119	369	117	3622.5	0.911
WASO (min)	53.7	86.0	74.4	74.0	4093.0	0.195
SL (min)	17.0	30.5	15.8	26.8	3725.5	0.845
REM L (min)	85.5	130	119	121	3761.0	0.203
NREM1%	9.24	11.0	11.4	8.73	3915.0	0.445
NREM2%	41.3	13.8	42.3	11.1	3916.0	0.607
NREM3%	27.3	17.9	25.2	12.8	3226.5	0.194
REM%	16.6	11.2	18.9	10.5	4265.5	0.070
AI	17.8	18.6	20.3	16.0	4082.5	0.096
AHI	5.40	11.0	1.70	5.90	2802.5	0.010*
PLMI	9.25	24.6	14.2	25.1	3806.5	0.105

Table 1. Demographic and polysomnographic characteristics of bipolar affective disorder (BPAD, n = 63) and recurrent depressive disorder (RDD, n = 126) patients. Group comparisons were conducted using one-way ANOVAs for parametric variables, Mann–Whitney U tests for non-parametric variables and Pearson's χ^2 tests for categorical variables. Significant values are in bold. %, percentage; AH, apnea–hypopnea; AHI, apnea–hypopnea index; AI, arousal index; BMI, body mass index kg/m²; D, relative density; ESS, Epworth Sleepiness Scale; F, one-way ANOVA F statistics; IQR, interquartile ranges; n, number; NREM, non-rapid eye movement; min, minute; REM, rapid eye movement; time; REM L, rapid eye movement latency; SL, sleep latency; SD, standard deviation; TST, total sleep time; WASO, wake after sleep onset; U, Mann–Whitney U statistics. *P < 0.05.

taking account of the sleep stage, and the sleeping position and its relative duration in total sleep time. A value > 1 indicates the predominance of sleep apnoea type during the night. For assessing sleep stage's and body position's contribution to the total number of apneas and hypopneas, we generated their respective ratios, i.e. number of apneas and hypopneas from NREM/total number of apneas + hypopneas (AH_{NREM}/AH).

Sleep disorders, other comorbidity, pharmacotherapy. Information regarding sleep disorders, other comorbid conditions and medications was retrieved from medical records. Diagnosis of sleep disorders was made by consultant sleep physicians, based on International Classification of Sleep Disorders third edition (ICSD-3)¹⁴. Recorded sleep disorders were subsequently included in further analysis. For statistical analysis, sleepwalking, sleep talking, sleep terrors, slow wave arousal disorders and other non-REM parasomnias were categorised as NREM parasomnia¹⁵, while supine- or REM-related OSA was included under the umbrella diagnosis of OSA. Moreover, unspecified sleep disorders (i.e. no identified organic sleep disorder from PSG but with a noted difficulty falling asleep or maintaining sleep), mild insomnia-like presentations with behaviourally induced insufficient sleep syndrome were both labelled as 'poor sleep quality' (PSQ) in the data analysis. Day-time sleepiness and excessive daytime somnolence was captured by the self-administered questionnaire Epworth Sleepiness Scale (ESS)¹⁶.

Medical records were searched for the diagnosis and medical history of other physical and psychiatric disorders and pharmacotherapeutic treatment plans. Subtypes of several disorders were grouped into one category for further analysis (e.g. personality disorder, chronic pain and arthritis). Another example is if a Nissan fundoplication was indicated in patients' medical records, a medical history of gastro-oesophageal reflux disease would be noted as one of patient's diagnoses. Additionally, individuals with body mass index (BMI) ≥ 30 were considered as obese¹⁵, which was then listed as comorbidity in our study.

Statistical analyses. Data was recorded and subsequently analysed using the statistical software IBM SPSS Statistics Version 25 (IBM Corp., 2017). Means (standard deviations) or medians (interquartile ranges, IQRs) were reported as descriptive statistics for continuous variables, while numbers of samples (percentages) were reported for categorical variables. When the assumption of normality was met, independent sample t-tests were then used to compare continuous variables between the BPAD and RDD group, and χ^2 tests for the comparison of categorical variables. For non-parametric variables, Mann–Whitney U tests and Fisher's exact tests were conducted as appropriate. If differences were observed in variables between both groups, subgroup analyses were carried out for further investigation. Regression analysis with backward elimination and natural log transformation of the dependent variable HI/AHI was performed, with independent factors the AHI, AHI_{NREM} , WASO,

N1%, N2% and TST, following exploratory results from Pearson correlation between HI/AHI, BMI, the sleep parameters and OSA severity metrics. The statistical significance level was set at $P < 0.05$.

Results

Socio-demographic and polysomnographic descriptive statistics is shown in Table 1. Sixty three BPAD patients, of whom 50.8% were women ($N = 32$), along with 126 RDD patients (49.2% women) who met the inclusion criteria, were investigated in the final analysis (see Table 1). The age of selected patients ranged from 18 to 66 years old, with a mean age of 41.8 ($SD = 12.4$) and 41.5 ($SD = 12.8$) years old in BPAD and RDD group, respectively (Table 1). BPAD patients' BMI was significantly higher than that of RDD patients' (32.9 ± 7.98 versus 28.6 ± 6.34 , $P < 0.001$, Mann–Whitney U test) (Table 1). Conversely, there was no significant difference in daytime sleepiness between two groups (ESS score: BPAD: 12.0 ± 13.0 versus RDD: 14.0 ± 9.0 , $P = 0.888$, one-way ANOVAs) and in majority of other sleep parameters (Table 1).

BPAD patients presented with overall higher sleep (Table 2) and non-sleep comorbidity (Supplementary Table 1) by comparison to RDD cohort.

Objective sleep measures. A total of 189 reports (Table 1) were analysed and variables of sleep architecture and sleep continuity were compared between the studied groups. No significant differences were noted in the sleep macrostructure. Patients with BPAD and RDD demonstrated a similar duration of sleep (TST: 379 ± 119 versus 369 ± 117 min, $P = 0.911$, Mann–Whitney U test). Moreover, our analysis showed that patients with BPAD and RDD experienced a similar level of arousals during the PSG (17.8 ± 18.6 versus 20.3 ± 16 , $P = 0.096$, Mann–Whitney U test). However, a greater AHI was recorded in BPAD patients in comparison to RDD patients (5.40 ± 11.0 versus 1.70 ± 5.90 , $P = 0.01$, Mann–Whitney U test), which reflected a greater prevalence of OSA in patients with BPAD relative to patients with RDD (Table 2).

Co-morbid sleep disorders. Only one patient (RDD) from our cohort presented with more than five events per hour of central sleep apnoea, and was thus excluded as per our eligibility criteria ($CSA > 50\%$ of the AHI). In both studied groups, OSA was the most prevalent comorbid sleep disorder among the seventeen sleep disorders recorded (Table 2). However, OSA was more frequently observed in BPAD patients relative to RDD patients (50.8% versus 29.3% , $P = 0.006$, Pearson's χ^2 test) (Table 2 and Fig. 1). Similarly, patients with BPAD were more often diagnosed with insomnia compared to patients with RDD (34.9% versus 15.0% , $P = 0.005$, Pearson's χ^2 test). Conversely, the analysis of medical records and PSGs of patients with RDD demonstrated that they more often suffered with a poor sleep quality (PSQ; Table 2), which upon objective analysis failed to reach the level of caseness for diagnosis of insomnia, or any other sleep disorders. The findings for other sleep disorders are also shown in Table 2.

We then set to investigate OSA as the most prevalent sleep disorder in our cohorts. The further analyses did not reveal any significant differences in overall AHI of the OSA patients between the two groups ($P = 0.357$, Mann–Whitney U test). However, BPAD patients presented with higher OSA severity than RDD patients (Fig. 2, $P = 0.036$, Pearson's χ^2 test). Both cohorts presented predominantly with OSA of mild severity (BPAD 62.5% versus 81.1% RDD, Fig. 2). The BPAD group had higher AHI in REM sleep ($P = 0.037$, Mann–Whitney U test), however, the relative density (AHI_{REM}/AHI) and the relative contribution to the total number of events (AHs_{REM}/AHs) was comparable between the two cohorts ($P = 0.086$ and $P = 0.420$, Mann–Whitney U test, respectively; Table 2).

Of note, RDD patients presented with the higher relative density of OSA during NREM (AHI_{NREM}/AHI), and the respective contribution to the overall events (AHs_{NREM}/AHs), was recorded as significantly higher in the RDD group ($P = 0.038$ and $P = 0.042$, Mann–Whitney U test, respectively; Table 2), perhaps suggestive of higher mechanistic vulnerability of this cohort to respiratory events during NREM sleep.

Of note is that in 75% of all patients, hypopneas dominated in almost 2/3 of all respiratory events. No differences were recorded between groups in the hypopnea index (HI) as fraction of the AHI (HI/AHI) in any of sleep stages (Table 2). In addition, correlational analyses suggested link between (a) overall milder OSA severity (BPAD: $r = -0.359$, $P = 0.044$ and RDD: $r = -0.413$, $P = 0.011$, Pearson correlation, respectively; Fig. 3), (b) milder OSA during NREM (BPAD: $r = -0.397$, $P = 0.025$, and RDD: $r = -0.495$, $P = 0.002$, Pearson correlation, respectively), and (c) the higher percentage of NREM2 sleep (BPAD: $r = 0.474$, $P = 0.006$, and RDD: $r = 0.339$, $P = 0.040$, Pearson correlation, respectively), and higher hypopnea prevalence in both cohorts (Supplementary Table 2). For RDD patients, an additional link was seen with reduced amount of time spent awake after falling asleep (WASO: $r = -0.387$, $P = 0.018$, Pearson correlation) and with a duration of sleep (TST: $r = 0.457$, $P = 0.004$, Pearson correlation; Supplementary Table 2). No associations were found between hypopneas and daytime somnolence, or with demographic descriptive in either group.

For BPAD patients, a significant association was found between BMI and AHI ($r = 0.555$, $P = 0.001$), AHI_{NREM} ($r = 0.456$, $P = 0.010$), and AHI_{REM} ($r = 0.361$, $P = 0.046$), but not with HI/AHI ($r = 0.043$, $P = 0.818$), nor for any of the sleep stages ($P > 0.05$). There were no significant links with the AHI or HI indices in RDD group (Supplementary Table 2).

Regression analyses showed that for the BPAD patients, decreasing AHI_{NREM} (-0.391 , $P = 0.012$) and increasing NREM2% of TST (0.469 , $P = 0.003$) were the sole two independent predictors of HI/AHI variance ($r^2 = 0.378$, $P = 0.001$). In line with other analyses, for RDD patients, the model was statistically significant for predicting 41% of the HI/AHI variance ($r^2 = 0.409$, $P < 0.001$), sharing with BPAD the AHI_{NREM} factor ($r^2 = -0.407$, $P = 0.006$) and the NREM2% of TST ($r^2 = 0.248$, $P = 0.078$) factors, in addition to WASO ($r^2 = -0.320$, $P = 0.024$).

Sleep disorders	BPAD		RDD		χ^2	P value
	n	%	n	%		
OSA	32	50.8	37	29.3	19.450	0.006**
Gender (female)	17	53.1	17	45.9	0.354	0.552
	Median	IQR	Median	IQR	U	
Age (years)	44.8	11.5	49.7	9.9	739.5	0.076
BMI (kg/m ²)	35.9	8.5	30.6	6.5	338.5	0.004*
ESS	14.0	7	13.0	9.0	521.5	0.846
AHI (e/h)	10.0	12.7	10.7	7.1	515.5	0.357
HI/AHI (e/h)	0.81	0.25	0.78	0.27	538.5	0.520
AHI _{REM} (e/h)	19.5	23.3	10.4	12.3	419.0	0.037*
AHI _{REM} /AHI (e/h)	1.67	2.03	1.44	1.61	357.0	0.086
AHs _{REM} /AHs (n)	0.25	0.39	0.19	0.40	525.0	0.420
HI/AHI in REM (e/h)	0.83	0.52	0.79	0.48	548.0	0.596
AHI _{NREM} (e/h)	8.9	12.2	9.4	9.6	585.0	0.933
AHI _{NREM} /AHI (e/h)	0.85	0.63	0.94	0.24	764.5	0.038*
AHs _{NREM} /AHs (n)	0.71	0.60	0.81	0.40	761.0	0.042
HI/AHI in NREM (e/h)	0.84	0.24	0.82	0.36	535	0.492
AHI _{supine} (e/h)	16.8	27.5	15.7	16.8	573.0	0.819
AHs _{supine} /AHs (n)	0.67	0.51	0.59	0.71	545.5	0.575
AHI _{Non-supine} (e/h)	5.1	5.8	5.4	9.2	570.0	0.791
AHs _{Non-supine} /AHs (n)	0.32	0.51	0.41	0.71	645.0	0.523
Other sleep disorders	n	%	n	%	χ^2	
Insomnia	22	34.9	20	15.0	8.816	0.005*
PLMD	9	14.3	23	18.3	0.470	0.544
NREM parasomnia	5	7.90	10	7.90	0.000	1.000
RLS	5	7.90	8	6.30	–	0.763
Idiopathic hypersomnia	4	6.30	11	8.70	0.326	0.777
PSQ	3	4.80	32	25.4	12.507	0.001*
Narcolepsy (I + II)	1	1.60	5	4.00	–	0.665
EFM	1	1.60	1	0.80	–	1.000
Sleep paralysis	1	1.60	0	0	–	0.333
DSPS	0		1	0.80	–	1.000
Drug-induced hypersomnolence	0		1	0.80	–	1.000
Catathrenia	0		1	0.80	–	1.000
Bruxism	0		1	0.80	–	1.000
CSA	0		1	0.80	–	1.000

Table 2. Comparison of obstructive sleep apnea metrics in obstructive sleep apnoea patients, and distribution of comorbid sleep disorders between patients with Bipolar Affective Disorder and patients with Recurrent Depressive Disorder. Group comparisons for categorical variables were conducted using Pearson's χ^2 tests for parametric variables and Fischer's Exact tests for non-parametric variables, and for continuous variables, the Independent-Samples Mann–Whitney U test. Significant values are in bold. %, percentage; AHs, total number of apneas and hypopneas; AHs_{REM}, number of apneas and hypopneas during REM sleep; BPAD, bipolar affective disorder; CSA, central sleep apnea; DSPS, delayed sleep phase syndrome; EFM, excessive fragmentary myoclonus; e/h, events per hour; HI/AHI, hypopneas index to apnea and hypopneas index; n, number; NREM parasomnia, non-rapid eye movement parasomnia; NREM, non-rapid eye movement sleep; OSA, obstructive sleep apnea; PLMD, periodic limb movement disorder; PSQ, poor sleep quality; RDD, recurrent depressive disorder; REM, rapid eye movement sleep; RLS, restless legs syndrome. * $P < 0.05$.

Other (non-sleep) co-morbidities. Descriptive statistics for other (non-sleep) comorbid conditions are shown in the Supplementary Table 1. In total, 75 comorbid conditions were recorded in the current study. Obesity (BMI ≥ 30) was the most prevalent comorbid condition in both patient groups, with a significantly greater prevalence in individuals with BPAD compared to individuals with RDD (52.4% versus 31.0%, $P = 0.007$, Pearson's χ^2 test) (Supplementary Table 1). In the BPAD group, the second most frequent comorbid conditions were jointly diabetes (14.3% versus 3.2%, $P = 0.011$, Fischer's Exact test) and hypothyroidism (14.3% versus 2.4%, $P = 0.003$, Fischer's Exact test), while hypertension was frequently reported in both groups (7.9% versus 7.9%, $P = 1.00$, Fischer's Exact test).

Furthermore, Fisher's exact tests revealed that several disorders were significantly more common in patients with BPAD than in patients with RDD, including asthma (11.1% versus 3.2%, $P = 0.044$), irritable bowel




Figure 1. Most prevalent sleep disorders in bipolar affective disorder (BPAD) and recurrent depressive disorder (RDD). Analysis was performed using Pearson's χ^2 test. *PLMD* periodic limb movement disorder, *PSQ* poor sleep quality. * $P < 0.05$, χ^2 test.




Figure 2. Graphical representation of the different distribution of obstructive sleep apnea (OSA) severity in patients with Bipolar Affective Disorder (BPAD) and Recurrent Depressive Disorder (RDD). The distribution of the OSA severity is statistically different between the two groups, $P = 0.036$ (Chi-Square test). Mild OSA, AHI 5–14.9 e/h; Moderate OSA, AHI 15–29.9 e/h; Severe OSA, > 30 e/h.

syndrome (IBS) (7.9% versus 0, $P = 0.004$), fibromyalgia (6.3% versus 0.8%, $P = 0.043$), migraine (6.3% versus 0.8%, $P = 0.043$), attention deficit hyperactivity disorder (ADHD) (4.8% versus 0, $P = 0.036$) and hyperlipidaemia (4.8% versus 0, $P = 0.036$).

Pharmacotherapy. Patients with BPAD and RDD differed in the number of medications taken ($P = 0.006$, Fischer's Exact test). The majority of patients with BPAD were prescribed at least two medications (17.5%), whereas patients with RDD were mostly treated by only one medication (32.5%). Furthermore, the number of medications taken by patients significantly varied, from no medication (6.30% versus 13.5%) to a combination of more than 15 medications (one patient in each group). Most frequently recorded pharmacological treatments for two cohorts are shown in Supplementary Table 3.

The most commonly used medication in the BPAD group was lamotrigine, an anticonvulsant and a mood stabilising medication, which was prescribed significantly more frequently than in the RDD group (27.0% versus 0.80%, $P < 0.001$, Fischer's Exact test). SSRIs, and specifically citalopram and sertraline, were the most frequently prescribed medications for mood stabilisation in the RDD group (19.8% and 12.7% respectively), and significantly more compared to BPAD group (1.60%, $P < 0.05$, Fischer's Exact test). Sodium valproate was another anticonvulsant and mood stabilising medication that was significantly more prescribed for patients with BPAD in our cohort (20.6% versus 0, $P < 0.001$, Fischer's Exact test; Supplementary Table 3). In contrast, no group difference was observed for pregabalin, a treatment that is often used in treating anxiety and sleep disorders such as RLS or PLMD and as an adjunctive medication for partial seizures in epilepsy (11.1% versus 6.3%, $P = 0.393$, Fischer's Exact test).




Figure 3. Scatter plot with best fit regression lines between the HI/AHI ratio and the AHI for patients with Bipolar Affective Disorder (BPAD) and Recurrent Depressive Disorder (RDD). *HI/AHI* hypopneas index to apnea and hypopnea index.

Perhaps unsurprisingly, patients in our cohort were also frequently treated with medications for sleep disturbances (Supplementary Table 3). In particular, patients with BPAD were more often prescribed with zopiclone relative to depressed patients (14.3% versus 4.8%, $P=0.042$, Fischer's Exact test). On the other hand, hypnotic medications such as benzodiazepines including diazepam (4.80% versus 1.60%, $P=0.335$, Fischer's Exact test), temazepam (3.20% versus 0.80%, $P=0.258$, Fischer's Exact test) and lorazepam (0 versus 1.6%, $P=0.553$, Fischer's Exact test) did not differ significantly between patients with BPAD and RDD. Descriptive statistics for other medications are shown in Supplementary Table 3.

Discussion

We report a strong association between OSA and insomnia, two most prevalent sleep disorders, and BPAD, in a selected cohort of patients from a tertiary sleep clinic. A significant link was also demonstrated between OSA and insomnia and RDD patients, in keeping with previous studies^{17–20}. However, this association was significantly less strong for RDD, which could be arguably explained by distinct metabolic profiles of our two cohorts²¹. By way of example, patients with BPAD in our study were reported to be more obese than their RDD counterparts, and they had a higher frequency of comorbid physical conditions including diabetes, hypothyroidism and asthma, which is consistent with previous epidemiological findings^{22,23}. Conversely, RDD patients most commonly reported mild sleep problems that did not reach full diagnostic casesness (PSQ). It is of note that investigations were done during patients' presumed full or partial remission, which arguably also explain lower prevalence of insomnia noted for both cohorts.

High prevalence and incidence of OSA have been previously reported in BPAD^{24–26}. In that background, some authors have argued that a reduction in noradrenaline and serotonin delivery to upper airway dilator motor neurons in sleep might contribute to reduced dilator muscle activity and increased upper airway obstruction, resulting in OSA^{27,28}. Perhaps consistently, our RDD patients were more often prescribed medications with REM-suppressing properties (e.g. mirtazapine and fluoxetine), which may be theoretically protective against respiratory related arousals and REM-related OSA. Conversely, however, other studies have suggested that chronic management with psychotropic medications can similarly inhibit the serotonergic pathway, and thus increase the upper airway resistance and eventually worsen symptoms in OSA^{29,30}. To date, the effects of psychotropic medications on the relationship between REM sleep and OSA in patients with affective disorders remain unclear and thus any inferences remain only conjectural. Moreover, our data did not account for possible non-adherence to the prescribed regimes, which is relatively common amongst the RDD and BPAD patients, and which may further skew any findings³¹.

The primary goal of our study was to investigate differences in sleep disturbances and the sleep macrostructure between BPAD and RDD. We failed to demonstrate any overt differences in their sleep macrostructure (Table 1). Whilst this is still a matter of controversy in the field of neuropsychiatry, it has been previously proposed by some authors that a lack of specific neurophysiological markers in affective disorders might suggest their common underlying neuromechanisms^{32,33}. To date, several underlying mechanisms of sleep dysregulation in affective disorders have been proposed. They include disbalance in the cholinergic-aminergic system^{34,35}, dysregulated sleep–wake synaptic activity^{36,37} and increased allostatic load³⁸; all of which are implicated in the pathophysiology

of both BPAD and RDD. Although current findings could not provide robust results for a specific hypothesis building, similarities in sleep architecture parameters may be similarly attributed to the use of antidepressants with REM suppressing or enhancing properties^{39,40}, which may reflect the modulatory role of monoamine system in sleep and affective regulation. In this study, patients with BPAD and RDD were commonly treated with SSRIs and SNRIs which help ameliorating depressive symptoms and reducing the elevated amount of REM sleep^{41–43}. However, due to the retrospective design of our study, neither causality or directionality of these associations can be deduced.

Another interesting finding of our study is relatively mild severity of recorded OSA in both psychiatric cohorts (Fig. 2), even in the presence of high prevalence of co-morbid obesity. Research evidence to date suggests a close relationship between being overweight and obesity with OSA⁴⁴. However, the extent of this relationship among different population groups, including those with psychiatric co-morbidity, is unclear. Obesity has been in past also linked with higher percentage of hypopneas⁴⁵, and in keeping, this was another striking finding in both of our cohorts (Fig. 3). As already mentioned, due to the retrospective and a real-world nature of our study, any possible mechanistic platform behind these observed phenotypes of OSA in RDD and BPAD remains unclear. For example, theoretically, these findings may reflect, at least in part, modulation of cortical arousal by antidepressant medications taken by our patients. Similarly, milder OSA severity during REM sleep in RDD patients, as observed in our study, could simply reflect an increased use of medications with a REM suppressing effect in this cohort group^{46,47}.

In addition, our study highlights several specific clinical issues. For example, the current gold standard treatment of OSA, positive airway pressure (PAP) therapy, is known to be poorly tolerated by majority of patients, and compliance with the treatment is especially challenging in patients with psychiatric co-morbidities. In future, baseline respiratory/sleep biomarkers, such as for instance the HI/AHI ratio in our study, could potentially offer a pivotal clinical insight and allow for a better pathophysiological characterisation of the phenotype of OSA, and accordingly lead to a more personalised treatment⁴⁸. For instance, in our study, we demonstrated higher proportion of the hypopneas in both RDD and BPAD cohorts. Although this remains a matter of some debate^{49–51}, similar OSA phenotype has been in past linked to lower PAP pressure requirements for the maintenance of airway's patency (i.e. to overcome the flow limitation in the dynamic closure of the airway), leading to increased tolerability of treatment^{50,52,53}. Comparably, analogous OSA phenotype in a RDD or BPAD patient, may guide an earlier clinical decision towards other types of therapy, such as with mandibular advancement device, known to be better tolerated by some patient groups⁴⁵.

Finally, hypopneas have been historically linked with both adaptive (sleep-promoting) and maladaptive (sleep-instability increasing) cortical arousals^{54,55}, with the latter subtype likely associated with a more severe OSA and higher cognitive⁵⁶, metabolic and physiologic deficits^{55,57}. Against that background, it is of note that both BPAD and RDD's affective symptomatology can lead to 'cognitive' hyperarousal, which in turn has been shown to increase spontaneous arousals from sleep⁵⁸. Spontaneous arousals of sleep, on the other hand, appear to share the same neurocircuitry and mechanisms to those of respiratory arousals in OSA⁵⁹. Thus, observed OSA phenotype in our patients may reflect a complex interplay of the RDD and BPAD biology, modulated by the idiosyncratic homeostatic and circadian pressure of sleep. Limited evidence to-date also suggests that patients with this particular phenotype of OSA (e.g. with increased overnight HI/AHI ratio and with associated hyperarousability) may clinically benefit from addition of low doses of sedative medication^{60,61} to their standard treatment protocols (e.g. MAD or PAP). Also, in keeping with promising results shown for OSA with other comorbid sleep disorders⁶², it is tempting to propose that in future, distinct cognitive behaviour therapy courses, especially those that target cognitive hyperarousal levels, and that are further tailored to the specific needs of the BPAD or RDD patients, may achieve similar beneficial results. In future, it will be vital to discern a neural mechanism behind affective symptomatology-driven hyperarousal and its effect on OSA-hypopneas and their physiologic fingerprint. Also, we will need to work out distinct cognitive, affective, and behavioural correlates of this interplay.

In summary, whilst all the findings we report can be arguably attributed to the limitations of our tertiary centre recruitment bias, occupational need, accessibility to health care, higher recorded metabolic²¹ and other comorbidity burden in BPAD cohort, as well as recorded differential treatment regimes, we believe they nonetheless merit further investigation. Importantly, they may provide an important clinical message in regards to a significant health system referral bias. For example, our findings could be taken to suggest that patients with RDD are more likely (more easily) to be referred relatively early in their illness progression, whilst suffering with their relatively mild complaints. Conversely, BPAD patients we investigated were more likely to be on polytherapy and with suspected well established metabolic syndrome, perhaps suggestive of much later referral in the course of their illness, despite their obvious (longer-standing) and significant sleep disorder burden (37.5% of moderate to severe OSA and 34.9% of insomnia for BPAD versus 19.9% and 15% for RDD, respectively). Finally, one should note that our findings are based on only one snapshot in the disease progression timeline of these two complex affective disorders, with no further assessment of the disease severity, and thus no further conclusions in regards to the association with the illness severity or its stage could be drawn. Various stages of BPAD and RDD (e.g. acute, mild, severe, manic episode, depression, remission, comorbid with anxiety and/or other disorders) very likely command differential sleep phenotypes, as of yet not fully understood. Future prospective multicentre studies should consider a multidisciplinary approach, including an active collaboration between psychiatric, internal medicine and sleep physicians, which would allow for more accurate and verifiable assessments of illness progression and help elucidate a viable and meaningful physiologic biomarkers for sleep phenotypes.

Received: 12 August 2022; Accepted: 29 May 2023

Published online: 31 May 2023

References

1. Rosenzweig, I. *et al.* Sleep apnoea and the brain: A complex relationship. *Lancet Respir. Med.* **3**, 404–414 (2015).
2. Eidelman, P., Talbot, L. S., Gruber, J., Hairston, I. & Harvey, A. G. Sleep architecture as correlate and predictor of symptoms and impairment in inter-episode bipolar disorder: Taking on the challenge of medication effects. *J. Sleep Res.* **19**, 516–524 (2010).
3. Landsness, E. C., Goldstein, M. R., Peterson, M. J., Tononi, G. & Benca, R. M. Antidepressant effects of selective slow wave sleep deprivation in major depression: A high-density EEG investigation. *J. Psychiatr. Res.* **45**, 1019–1026 (2011).
4. Peterson, M. J. & Benca, R. M. Sleep in mood disorders. *Psychiatr. Clin. N. Am.* **29**, 1009–1032. <https://doi.org/10.1016/j.psc.2006.09.003> (2006) (abstract ix).
5. American Psychiatric, A. Diagnostic and statistical manual of mental disorders. *Fifth Ed.* <https://doi.org/10.1176/appi.books.9780890425596> (2013).
6. Organization, W. H. *World Health Organization.* (2022). *ICD-11: International Classification of Diseases (11th revision)*. (World Health Organization, 2022).
7. Nutt, D., Wilson, S. & Paterson, L. Sleep disorders as core symptoms of depression. *Dialogues Clin. Neurosci.* **10**, 329–336. <https://doi.org/10.31887/DCNS.2008.10.3/dnutt> (2008).
8. Esaki, Y. *et al.* Association between circadian activity rhythms and mood episode relapse in bipolar disorder: A 12-month prospective cohort study. *Transl. Psychiatry* **11**, 525. <https://doi.org/10.1038/s41398-021-01652-9> (2021).
9. Bradley, A. J. *et al.* Sleep and circadian rhythm disturbance in bipolar disorder. *Psychol. Med.* **47**, 1678–1689. <https://doi.org/10.1017/S0033291717000186> (2017).
10. Gold, A. K. & Kinrys, G. Treating circadian rhythm disruption in bipolar disorder. *Curr. Psychiatry Rep.* **21**, 14. <https://doi.org/10.1007/s11920-019-1001-8> (2019).
11. Pearson, O. *et al.* The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review. *J. Affect. Disord.* **327**, 207–216. <https://doi.org/10.1016/j.jad.2023.01.114> (2023).
12. Wasserman, D. *et al.* Restricted truncal sagittal movements of rapid eye movement behaviour disorder. *NPJ Parkinsons Dis.* **8**, 26. <https://doi.org/10.1038/s41531-022-00292-0> (2022).
13. Campbell, I. G. EEG recording and analysis for sleep research. *Curr. Protoc. Neurosci.* <https://doi.org/10.1002/0471142301.ns1002s49> (2009).
14. Sateia, M. J. International classification of sleep disorders-third edition: Highlights and modifications. *Chest* **146**, 1387–1394. <https://doi.org/10.1378/chest.14-0970> (2014).
15. Organization, W. H. (World Health Organization, 2016).
16. Johns, M. W. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. *Sleep* **14**, 540–545 (1991).
17. Stubbs, B. *et al.* The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis. *J. Affect. Disord.* **197**, 259–267 (2016).
18. Sharafkhan, A., Giray, N., Richardson, P., Young, T. & Hirshkowitz, M. Association of psychiatric disorders and sleep apnea in a large cohort. *Sleep* **28**, 1405–1411. <https://doi.org/10.1093/sleep/28.11.1405> (2005).
19. Soehner, A. M., Kaplan, K. A. & Harvey, A. G. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. *J. Affect. Disord.* **167**, 93–97 (2014).
20. Lu, M. K. *et al.* Sleep apnea is associated with an increased risk of mood disorders: A population-based cohort study. *Sleep Breath* **21**, 243–253. <https://doi.org/10.1007/s11325-016-1389-x> (2017).
21. Babson, K. A., Del Re, A., Bonn-Miller, M. O. & Woodward, S. H. The comorbidity of sleep apnea and mood, anxiety, and substance use disorders among obese military veterans within the Veterans Health Administration. *J. Clin. Sleep Med.* **9**, 1253–1258 (2013).
22. Crump, C., Sundquist, K., Winkleby, M. A. & Sundquist, J. Comorbidities and mortality in bipolar disorder: A Swedish national cohort study. *JAMA Psychiat.* **70**, 931–939 (2013).
23. Rocha, P. & Correa, H. The impact of clinical comorbidities and residual depressive symptoms in sleep quality in euthymic/interepisodic bipolar subjects. *Psychiatry Res.* **268**, 165–168 (2018).
24. Chang, E. T. *et al.* Risk of obstructive sleep apnea in patients with bipolar disorder: A nationwide population-based cohort study in Taiwan. *Psychiatry Clin. Neurosci.* **73**, 163–168 (2019).
25. Kelly, T., Douglas, L., Denmark, L., Brasuell, G. & Lieberman, D. Z. The high prevalence of obstructive sleep apnea among patients with bipolar disorders. *J. Affect. Disord.* **151**, 54–58 (2013).
26. Szaulińska, K. *et al.* Obstructive sleep apnea in severe mental disorders. *Psychiatr. Pol.* **49**, 883–895 (2015).
27. Munkholm, K., Bräuner, J. V., Kessing, L. V. & Vinberg, M. Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. *J. Psychiatr. Res.* **47**, 1119–1133 (2013).
28. Bai, Y. M. *et al.* Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls. *Bipolar Disord.* **17**, 269–277 (2015).
29. Kuroki, T., Nagao, N. & Nakahara, T. Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. *Prog. Brain Res.* **172**, 199–212 (2008).
30. Shirani, A., Paradiso, S. & Dyken, M. E. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. *Sleep Med.* **12**, 591–597 (2011).
31. Semahegn, A. *et al.* Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis. *Syst. Rev.* **9**, 17. <https://doi.org/10.1186/s13643-020-1274-3> (2020).
32. Hudson, J. I. *et al.* Polysomnographic characteristics of young manic patients: Comparison with unipolar depressed patients and normal control subjects. *Arch. Gen. Psychiatry* **49**, 378–383 (1992).
33. Harvey, A. G., Murray, G., Chandler, R. A. & Soehner, A. Sleep disturbance as transdiagnostic: Consideration of neurobiological mechanisms. *Clin. Psychol. Rev.* **31**, 225–235 (2011).
34. Janowsky, D., Davis, J., El-Yousef, M. K. & Sekerke, H. J. A cholinergic-adrenergic hypothesis of mania and depression. *Lancet* **300**, 632–635 (1972).
35. McCarley, R. W. REM sleep and depression: common neurobiological control mechanisms. *Am. J. Psychiatry* (1982).
36. Borbély, A. A., Baumann, F., Brandeis, D., Strauch, I. & Lehmann, D. Sleep deprivation: Effect on sleep stages and EEG power density in man. *Electroencephalogr. Clin. Neurophysiol.* **51**, 483–493 (1981).
37. Borbély, A. A. A two process model of sleep regulation. *Hum. Neurobiol.* **1**, 195–204 (1982).
38. Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A. & Riemann, D. REM sleep dysregulation in depression: State of the art. *Sleep Med. Rev.* **17**, 377–390 (2013).
39. Gedge, L., Lazowski, L., Murray, D., Jokic, R. & Milev, R. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. *Neuropsychiatr. Dis. Treat.* **6**, 501 (2010).
40. Wichniak, A., Wierzbicka, A., Wałęcka, M. & Jernajczyk, W. Effects of antidepressants on sleep. *Curr. Psychiatry Rep.* **19**, 63 (2017).
41. Hirshkowitz, M. & Bhandari, H. In *Sleep Disorders Medicine* 103–118 (Springer, 2017).
42. Tribi, G. G., Wetter, T. C. & Schredl, M. Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers. *Sleep Med. Rev.* **17**, 133–142 (2013).
43. Wilson, S. & Argyropoulos, S. Antidepressants and sleep. *Drugs* **65**, 927–947 (2005).
44. Dong, Z. *et al.* Association of overweight and obesity with obstructive sleep apnoea: A systematic review and meta-analysis. *Obes. Med.* **17**, 100185. <https://doi.org/10.1016/j.obmed.2020.100185> (2020).

45. Mathew, R. & Castriotta, R. J. High hypopnea/apnea ratio (HAR) in extreme obesity. *J. Clin. Sleep Med.* **10**, 391–396. <https://doi.org/10.5664/jcsm.3612> (2014).
46. Kraiczi, H., Hedner, J., Dahlof, P., Eijnell, H. & Carlson, J. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. *Sleep* **22**, 61–67 (1999).
47. Hanzel, D. A., Proia, N. G. & Hudgel, D. W. Response of obstructive sleep apnea to fluoxetine and protriptyline. *Chest* **100**, 416–421. <https://doi.org/10.1378/chest.100.2.416> (1991).
48. Gulati, A., Ali, M., Davies, M., Quinnell, T. & Smith, I. A prospective observational study to evaluate the effect of social and personality factors on continuous positive airway pressure (CPAP) compliance in obstructive sleep apnoea syndrome. *BMC Pulm. Med.* **17**, 56. <https://doi.org/10.1186/s12890-017-0393-7> (2017).
49. Tang, A. L. *et al.* Obstructive sleep apnea resolution in hypopnea- versus apnea-predominant children after adenotonsillectomy. *Otolaryngol. Head Neck Surg.* **155**, 670–675. <https://doi.org/10.1177/0194599816652387> (2016).
50. Yu, J. L. *et al.* Influence of apnea vs hypopnea predominance in predicting mean therapeutic positive airway pressures among patients with obstructive sleep apnea. *J. Clin. Sleep Med.* **17**, 2171–2178. <https://doi.org/10.5664/jcsm.9342> (2021).
51. Op de Beeck, S. *et al.* Endotypic mechanisms of successful hypoglossal nerve stimulation for obstructive sleep apnea. *Am. J. Respir. Crit. Care Med.* **203**, 746–755. <https://doi.org/10.1164/rccm.202006-2176OC> (2021).
52. Bosi, M. *et al.* Qualitative phenotyping of obstructive sleep apnea and its clinical usefulness for the sleep specialist. *Int. J. Environ. Res. Public Health.* <https://doi.org/10.3390/ijerph17062058> (2020).
53. Landry, S. A. *et al.* Therapeutic CPAP level predicts upper airway collapsibility in patients with obstructive sleep apnea. *Sleep* <https://doi.org/10.1093/sleep/zsx056> (2017).
54. Parekh, A. *et al.* Altered K-complex morphology during sustained inspiratory airflow limitation is associated with next-day lapses in vigilance in obstructive sleep apnea. *Sleep* <https://doi.org/10.1093/sleep/zsab010> (2021).
55. Gnoni, V. *et al.* Cyclic alternating pattern in obstructive sleep apnea: A preliminary study. *J. Sleep Res.* **30**, e13350. <https://doi.org/10.1111/jsr.13350> (2021).
56. Gnoni, V. *et al.* Distinct cognitive changes in male patients with obstructive sleep apnoea without co-morbidities. *Front. Sleep.* <https://doi.org/10.3389/frsle.2023.1097946> (2023).
57. Bucks, R. S., Olaithe, M., Rosenzweig, I. & Morrell, M. J. Reviewing the relationship between OSA and cognition: Where do we go from here?. *Respirology* **22**, 1253–1261. <https://doi.org/10.1111/resp.13140> (2017).
58. Chen, H. C., Lin, C. M., Lee, M. B. & Chou, P. The relationship between pre-sleep arousal and spontaneous arousals from sleep in subjects referred for diagnostic polysomnograms. *J. Chin. Med. Assoc.* **74**, 81–86. <https://doi.org/10.1016/j.jcma.2011.01.016> (2011).
59. Mesquita, J. *et al.* Respiratory and spontaneous arousals in patients with Sleep Apnea Hypopnea Syndrome. *Annu. Int. Conf. IEEE Eng. Med. Biol. Soc.* **2012**, 6337–6340. <https://doi.org/10.1109/EMBC.2012.6347443> (2012).
60. Eckert, D. J. *et al.* Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. *Clin. Sci. (Lond.)* **120**, 505–514. <https://doi.org/10.1042/CS20100588> (2011).
61. Mason, M., Cates, C. J. & Smith, I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. *Cochrane Database Syst. Rev.* <https://doi.org/10.1002/14651858.CD011090.pub2> (2015).
62. Sweetman, A., Farrell, S., Wallace, D. M. & Crawford, M. The effect of cognitive behavioural therapy for insomnia in people with comorbid insomnia and sleep apnoea: A systematic review and meta-analysis. *J. Sleep Res.* <https://doi.org/10.1111/jsr.13847> (2023).

Acknowledgements

This research was funded in whole, or in part, by the Wellcome Trust [103952/Z/14/Z]. For the purpose of open access, author IR has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. This paper represents independent research in part funded by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The authors are grateful for all the kind support provided by members of the Sleep and Brain Plasticity Centre (KCL) and Sleep Disorders Centre (GSTT) at various stages of this manuscript preparation. Part of these data were previously shown in a form of a poster presentation at World Sleep Congress in Vancouver, 2019.

Author contributions

P.D., D.O.R. and I.R. designed and conducted the study. Y.L., C.P. and P.D. analysed and collected data. All authors were involved in reviewing and drafting of the manuscript.

Competing interests

PD, DOR and IR designed and conducted the study. YL and PD analysed and collected data. All authors were involved in reviewing and drafting of the manuscript. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-023-36083-7>.

Correspondence and requests for materials should be addressed to I.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023